FDA pulls Covid antibody treatment because it's not effective against dominant omicron variants

The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
source

Related posts:

Qatar to ban beer at World Cup stadiums in dramatic reversal two days before tournament starts Black Friday car deals are hard to come by even as prices ease. Here's what to expect Online shoppers spent a record amount on Thanksgiving Flu hospitalizations increase nearly 30% as U.S. enters holiday season